Does Drugs That Prolong The Qt Interval Interact with Rozanolixizumab?
Drugs That Prolong The Qt Interval and Rozanolixizumab have a moderate drug interaction according to U.S. FDA drug labeling data. Concomitant use may lower systemic exposures and reduce effectiveness. Closely monitor for reduced effectiveness. The mechanism involves competition for human neonatal fc receptor (fcrn) binding. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.
- Severity
- Moderate
- Rozanolixizumab Class
- Neonatal Fc Receptor Blocker
- Management
- Monitor for effects
- Data Source
- U.S. FDA via OpenFDA
How This Interaction Works
The interaction between Drugs That Prolong The Qt Interval and Rozanolixizumab occurs because competition for human neonatal fc receptor (fcrn) binding. Clinically, this means concomitant use may lower systemic exposures and reduce effectiveness. closely monitor for reduced effectiveness. This is classified as a moderate interaction. While it may not require stopping either medication, your healthcare provider should be aware you are taking both so they can monitor for potential effects and adjust treatment if necessary.
What To Tell Your Doctor or Pharmacist
If you are taking Drugs That Prolong The Qt Interval and your doctor is considering prescribing Rozanolixizumab (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider